– Presentations Will Highlight Luspatercept Phase 3 Trial Designs, ACE-083 Phase 1 Trial Results, and the First Clinical Candidate from Acceleron’s New IntelliTrapTM Discovery Platform –

– Presentations to be given by members of Acceleron and Celgene management and external clinical experts –

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that it will host its Research and Development (R&D) Day for investors and analysts on Friday, October 23, 2015. The event will take place from 9:00 a.m. to 12:00 p.m. EDT in New York City.

At R&D Day, Acceleron and its collaboration partner, Celgene, will review the Phase 3 clinical development plan for luspatercept in myelodysplastic syndromes (MDS) and beta-thalassemia.

Acceleron will present preliminary Phase 1 results from ACE-083, its locally-acting muscle therapeutic, and provide updates on sotatercept and dalantercept in chronic kidney disease and cancer, respectively. In addition, the company will introduce its new drug discovery platform, IntelliTrapTM and ACE-2494, a systemic muscle therapeutic and the first clinical candidate to emerge from this platform.

Along with the Acceleron team, presentations will be given by outside experts to discuss the luspatercept clinical program and disease treatments, including MDS, beta-thalassemia and muscular dystrophies.

Guest speakers:

  • Jay Backstrom, M.D., M.P.H., Senior Vice President, Hematology & Oncology R&D, Global Head Regulatory Affairs, Celgene
  • Uwe Platzbecker, M.D., Professor of Hematology and Head of the MDS Program, University Hospital Dresden, Germany
  • Domenica Cappellini, M.D., Director of the Department of Clinical Sciences, Director of the Unit of Internal Medicine, University of Milan, Italy
  • Anthony Amato, M.D., Vice-Chairman, Department of Neurology, Brigham and Women’s Hospital, Boston

The live webcast of the event will be accessible from the “Investors & Media” section of the company's website, www.acceleronpharma.com.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-beta) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical therapeutic candidates with novel mechanisms of action. These therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.

Acceleron Pharma Inc.Todd James, 617-649-9393Senior Director, Corporate CommunicationsorMedia:Suda Communications LLCMaureen L. Suda, 585-387-9248

Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.